runit reported results from a Korean clinical study showing how its Lunit SCOPE IO tissue analysis software helped predict prognosis for patients with stage II-III colon cancer treated with curative surgery and adjuvant therapy. did.
Lunit SCOPE IO is a deep learning-based tumor-infiltrating lymphocyte (TIL) analyzer consisting of two complementary learning models developed for cell detection and tissue segmentation. It analyzes the tumor microenvironment based on hematoxylin and eosin analysis, a common testing technique used in research to provide a detailed view of tissue architecture, and provides AI-based predictive clinical outcome information. Masu.
of retrospective studywas announced in NPJ Precision Oncology, conducted by researchers from Seoul National University Bundang Hospital, Seoul National University of Medicine, and Lunit. Researchers evaluated the clinical utility of AI-based spatial TIL analysis for predicting post-treatment prognosis in 289 patients with stage II-III colon cancer.
Patients with confirmed recurrence showed significantly lower interstitial TIL density compared to patients without recurrence. The study also clearly identified high-, intermediate-, and low-risk groups. These groups predicted recurrence-free survival and were independently associated with clinical outcomes after adjusting for other clinical factors.